99% Immunosuppressive Drug Tacrolimus Powder Anti Inflammatory

 99% Immunosuppressive Drug Tacrolimus Powder Anti-Inflammatory Drug Tacrolimus CAS 104987-11-3

Product Name: Tacrolimus

CAS: 104987-11-3
MF: C44 H69 N O12
MW: 804.02
Melting point: 113-115°C
Boiling point: 871.7±75.0 °C
Storage temp.: −20°C

Description:

Tacrolimus, isolated from the microorganism Streptomyces tsukubaensis, is a macrolide immunosuppressant developed by Fujisawa for organ transplantation. It displays similar but more potent immunosuppressive activity than cyclosporin. It inhibits both cell mediated and humoral immune responses.

In animal models of organ transplantation, tacrolimus has been shown to prolong survival of hepatic, renal, cardiac, small intestine, pancreatic and skin allografts and to reverse cardiac and renal allograft rejection. It has been used effectively in humans as rescue or primary immunosuppressant therapy in liver or kidney transplantation.

Usage:

FK-506 (Tacrolimus) is a macrolide immunosuppressive drug that is mainly used after allogeneic organ transplant to reduce the activity of the patient's immune system

Test:CAS: 104987-11-3 Tacrolimus

Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug.It was discovered in 1984 from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis. Tacrolimus is chemically known as a macrolide. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription.